Abiraterone is associated with improved quality of life relative to docetaxel in men with hormone-naïve prostate cancer, shows an analysis of contemporaneously randomized participants of the STAMPEDE trial.
The combination of cabozantinib and atezolizumab has antitumor activity and a manageable safety profile in men with metastatic castration-resistant prostate cancer, indicate preliminary trial data.
The patient-reported outcomes from the CARD trial of third-line cabazitaxel in men with metastatic castration-resistant prostate cancer add support for using the taxane in this setting, say researchers.
The 8-year results from the phase 3 CHHiP trial have confirmed the noninferiority of moderately hypofractionated radiotherapy delivering 60 Gy in 20 fractions to the conventional regimen for the control of localized prostate cancer.
Metastasis-directed therapy for oligometastatic recurrent prostate cancer continues to be associated with better androgen deprivation therapy-free survival relative to surveillance at 5 years, show follow-up findings from the STOMP trial.
Combining a single nucleotide polymorphism-based genetic risk score for prostate cancer with family history could improve the stratification of inherited risk and help personalize screening strategies, research suggests.
Real-world data show comparable patient reported functional outcomes and health-related quality of life between nonmetastatic prostate cancer patients who were treated with moderately hypofractionated or conventionally fractionated radiation therapy.
The risk for clinically significant prostate cancer rises with age, report researchers who believe that this should be taken into account in the optimization of screening practices.
A behavioral intervention to increase vegetable consumption does not reduce the risk for disease progression over 2 years in men with early-stage prostate cancer undergoing active surveillance, phase 3 study data show.
Biochemical relapse-free survival and overall survival rates are comparable in men with localized prostate cancer who start androgen-deprivation therapy before or at the same time as dose-escalated prostate radiotherapy, phase 3 study data show.
Baseline prostate-specific antigen levels in men screened between the ages of 55 and 60 years are significantly associated with long-term risk for clinically significant prostate cancer, shows an analysis of data from the PLCO Cancer Screening Trial.
Men with favorable- and unfavorable-risk prostate cancer who undergo prostatectomy report worse urinary incontinence at 5 years than men treated with other contemporary management options, US research shows.
Pembrolizumab monotherapy shows activity against both RECIST-measurable and bone-predominant treatment-refractory metastatic castration-resistant prostate cancer, results of the KEYNOTE-199 phase 2 trial show.
Prostate cancer has undergone “reverse migration” away from indolent disease and toward more aggressive presentation in the USA following recommendations against prostate-specific antigen screening, say researchers.
Researchers have been unable to show that single-dose radiotherapy is not inferior to multifraction radiotherapy in terms of ambulatory status in patients with metastatic prostate, lung, or breast cancer and spinal cord or cauda equina compression.
DSTP3086S, a humanized immunoglobulin G1 monoclonal antibody that targets six-transmembrane epithelial antigen of the prostate 1 has shown promising results in a phase 1 study of metastatic castration-resistant prostate cancer.